šŸ“£ VC round data is live. Check it out!

Cibus Valuation Multiples

Discover Cibus' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Vittia, Atlantic International, Insumos AgroquĆ­micos, Delta Giri Wacana and more.

Cibus Overview

About Cibus

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.


Founded

2010

HQ

United States

Employees

159

Website

cibus.com

Financials (LTM)

Revenue: $5M
EBITDA: ($71M)

EV

$114M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cibus Financials

Cibus reported last 12-month revenue of $5M and negative EBITDA of ($71M).

In the same LTM period, Cibus generated $5M in gross profit, ($71M) in EBITDA losses, and had net loss of ($103M).

Revenue (LTM)


Cibus P&L

In the most recent fiscal year, Cibus reported revenue of $4M and EBITDA of ($83M).

Cibus is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (2267%), and net margin of (3492%).

See analyst estimates for Cibus
LTMLast FY202320242025202620272028
Revenue$5M$4M$2M$4M$4M
Gross Profit$5M$4M$2M$4M$4M
Gross Margin96%100%100%100%100%
EBITDA($71M)($83M)($314M)($242M)($91M)
EBITDA Margin(1313%)(2267%)(17284%)(5670%)(2494%)
EBIT Margin(1240%)(1854%)(3823%)(1806%)(1854%)
Net Profit($103M)($127M)($268M)($251M)($127M)
Net Margin(1912%)(3492%)(14729%)(5898%)(3492%)

Financial data powered by Morningstar, Inc.

Cibus Stock Performance

Cibus has current market cap of $112M, and enterprise value of $114M.

Market Cap Evolution


Cibus' stock price is $1.47.

Cibus share price increased by 2.8% in the last 30 days, and by 6.5% in the last year.

Cibus has an EPS (earnings per share) of $-1.66.

See more trading valuation data for Cibus
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$114M$112M2.8%2.8%-25.8%6.5%$-1.66

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cibus Valuation Multiples

Cibus trades at 21.2x EV/Revenue multiple, and (1.6x) EV/EBITDA.

See NTM and 2027E valuation multiples for Cibus

EV / Revenue (LTM)


Cibus Financial Valuation Multiples

As of June 2, 2026, Cibus has market cap of $112M and EV of $114M.

Cibus has a P/E ratio of (1.1x).

LTMLast FY202320242025202620272028
EV/Revenue21.2x31.3x62.7x26.7x31.3x
EV/EBITDA(1.6x)(1.4x)(0.4x)(0.5x)(1.3x)
EV/EBIT(1.7x)(1.7x)(1.6x)(1.5x)(1.7x)
EV/Gross Profit22.0x31.3x62.7x26.7x31.3x
P/E(1.1x)(0.9x)(0.4x)(0.4x)(0.9x)
EV/FCF(2.1x)(2.2x)(2.3x)(1.9x)(2.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cibus Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cibus Margins & Growth Rates

Cibus grew revenue by 114% but EBITDA decreased by 34% in the last fiscal year.

In the most recent fiscal year, Cibus reported gross margin of 100%, EBITDA margin of (2267%), and net margin of (3492%).

See estimated margins and future growth rates for Cibus

Cibus Margins

Last FY202420252026202720282029
Gross Margin100%100%100%94%
EBITDA Margin(2267%)(5670%)(2494%)(695%)
EBIT Margin(1854%)(1806%)(1854%)(547%)
Net Margin(3492%)(5898%)(3492%)(889%)
FCF Margin(1406%)(1381%)(1406%)(771%)

Cibus Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth114%135%(15%)114%
Gross Profit Growth101%135%(15%)101%
EBITDA Growth(34%)(23%)(62%)(40%)
EBIT Growth(37%)11%(12%)(37%)
Net Profit Growth(46%)(6%)(49%)(46%)
FCF Growth17%16%(13%)17%

Data powered by FactSet, Inc. and Morningstar, Inc.

Cibus Operational KPIs

Cibus' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.

Cibus' Rule of 40 is (581%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cibus' Rule of X is (410%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Cibus
LTMLast FY202320242025202620272028
Rule of 40(1221%)(581%)---
Bessemer Rule of X(1084%)(410%)---
Revenue per Employee-$0.0M---
Opex per Employee-$0.4M---
R&D Expenses to Revenue719%1215%2332%1183%1215%
Opex to Revenue-1954%3923%1906%1954%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Vittia0.9x0.9x6.2x6.6x
Atlantic International0.5x0.5x(4.6x)-
Insumos AgroquĆ­micos34.9x-307.9x-
Delta Giri Wacana0.8x-7.5x-
Paramonga1.3x-6.2x-
Soquimich Comercial0.6x-8.5x-
ArcticZymes7.4x6.8x39.1x49.7x
3D Medicines1.2x-(2.6x)-

This data is available for Pro users. Sign up to see all Cibus competitors and their valuation data.

Start Free Trial

Cibus VC Funding History

Before going public, Cibus raised $131M in total equity funding, across 3 rounds.


Cibus Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jun-18Series CAlexandria Venture Investments; Cormorant Asset Management; Fidelity$70M-Cibus, a San Diego-based agtech company, develops gene editing technology via its Rapid Trait Development System (RTDS) to create crops with improved traits like herbicide tolerance, higher yields, drought resistance, and disease resistance without introducing foreign DNA, distinguishing it from traditional GMO methods. The company raised $70 million in its Series C funding round on approximately June 26-27, 2018, led by Fidelity Management and Research Company, with participation from Alexandria Venture Investments and Cormorant Asset Management. This brought total funding to around $127-131 million at the time. Cibus had launched its first product, SU Canola (also called Falco), a non-GMO sulfonylurea herbicide-tolerant canola that received regulatory approval in the US and Canada, capturing 4% of the US canola market by late 2018. The technology enables precise gene edits for specific characteristics in crops including rice, flax, potato, wheat, corn, peanut, and soybean. Farmers benefit from reduced herbicide use through better weed control with SU Canola. The company was burning cash on R&D and admin costs as a biotech firm commercializing seeds directly to farmers, with plans to license traits to seed companies for royalties.
Jul-17Series B-$57M--
Feb-15Series A-$4M-Cibus raised $4.3 million in Series A funding in February 2015. The company's early-stage funding reflects its position as a pre-revenue or minimal-revenue agricultural biotechnology firm at that time. Cibus subsequently merged with an entity based on SEC filings referencing Cibus Global and developed plant gene-editing technologies, including TALEN-based traits for agricultural applications. The company later pursued public market activities, as evidenced by SEC registration statements. By 2024, the investment advisory operations had raised over $1 billion across multiple funds focused on sustainable food and agriculture investments, though this represents a different business line from the original core genetics company.

Acquisitions by Cibus

Cibus has acquired 1 company to date.

Last acquisition by Cibus was on January 17th 2023. Cibus acquired Calyxt for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Cibus

Calyxt
Description
Calyxt is a Roseville-headquartered agbiotech company engineering healthier crops via its TALEN gene-editing platform. It develops high-oleic soybean oil launched in 2019, wheat varieties with reduced gluten for baking, and alfalfa with improved feed quality. Partnerships with Bunge and others enable commercial production on thousands of acres. The firm focuses on non-GMO traits that meet consumer demands for cleaner-label foods without sacrificing yield.
HQ CountryUnited States
HQ City
Minnesota City, MN
Deal Date17 Jan 2023
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Cibus acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cibus

When was Cibus founded?Cibus was founded in 2010.
Where is Cibus headquartered?Cibus is headquartered in United States.
How many employees does Cibus have?As of today, Cibus has over 159 employees.
Who is the CEO of Cibus?Cibus' CEO is Peter Beetham.
Is Cibus publicly listed?Yes, Cibus is a public company listed on Nasdaq.
What is the stock symbol of Cibus?Cibus trades under CBUS ticker.
When did Cibus go public?Cibus went public in 2017.
Who are competitors of Cibus?Cibus main competitors include Vittia, Atlantic International, Insumos AgroquĆ­micos, Delta Giri Wacana, Paramonga, Soquimich Comercial, ArcticZymes, 3D Medicines, Clover Corp, Livestock Improvement.
What is the current market cap of Cibus?Cibus' current market cap is $112M.
What is the current revenue of Cibus?Cibus' last 12 months revenue is $5M.
What is the current revenue growth of Cibus?Cibus revenue growth (NTM/LTM) is 92%.
What is the current EV/Revenue multiple of Cibus?Current revenue multiple of Cibus is 21.2x.
Is Cibus profitable?No, Cibus is not profitable.
What is the current EBITDA of Cibus?Cibus has negative EBITDA and is not profitable.
What is Cibus' EBITDA margin?Cibus' last 12 months EBITDA margin is (1313%).
What is the current EV/EBITDA multiple of Cibus?Current EBITDA multiple of Cibus is (1.6x).
What is the current FCF of Cibus?Cibus' last 12 months FCF is ($55M).
What is Cibus' FCF margin?Cibus' last 12 months FCF margin is (1021%).
What is the current EV/FCF multiple of Cibus?Current FCF multiple of Cibus is (2.1x).
How many companies Cibus has acquired to date?As of June 2026, Cibus has acquired 1 company.
What was the largest acquisition by Cibus?None of the M&A deals Cibus has completed have disclosed valuations.
What companies Cibus acquired?Cibus acquired Calyxt.
In how many companies Cibus has invested to date?Cibus hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Cibus

Lists including Cibus

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial